Denali Therapeutics Inc [DNLI] stock prices are up 5.91% to $31.35 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNLI shares have gain 15.90% over the last week, with a monthly amount glided 21.79%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Cantor Fitzgerald downgraded its rating to Neutral on October 07, 2024. On December 13, 2023, Citigroup initiated with a Buy rating and assigned a price target of $32 on the stock. B. Riley Securities started tracking with a Buy rating for this stock on September 06, 2023, and assigned it a price target of $38. In a note dated January 30, 2023, SVB Securities initiated an Outperform rating and provided a target price of $50 on this stock.
The stock price of Denali Therapeutics Inc [DNLI] has been fluctuating between $14.56 and $32.13 over the past year. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $31.35 at the most recent close of the market. An investor can expect a potential return of 27.59% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
The Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.02% with Operating Profit Margin at 1.65%, Pretax Profit Margin comes in at 1.4%, and Net Profit Margin reading is 1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.76 points at the first support level, and at 28.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.20, and for the 2nd resistance point, it is at 33.05.
Ratios To Look Out For
It’s worth pointing out that Denali Therapeutics Inc [NASDAQ:DNLI]’s Current Ratio is 9.98. Further, the Quick Ratio stands at 9.98, while the Cash Ratio is 1.04.
Transactions by insiders
Recent insider trading involved ALEXANDER SCHUTH, Officer, that happened on Nov 07 ’24 when 15558.0 shares were purchased. Director, SATO VICKI L completed a deal on Nov 01 ’24 to sell 3080.0 shares. Meanwhile, President and CEO Watts Ryan J. sold 40000.0 shares on Oct 18 ’24.
